- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03929510
Recruitment Status Completed
First Posted April 29, 2019
Last update posted July 24, 2019
This study will investigate the absorption, distribution, metabolism and excretion (ADME) of 14C PF-06651600 and characterize plasma, fecal and urinary radioactivity and identify any metabolites, if possible, of 14C PF-06651600 in humans.
|Experimental: Period A
Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
|Experimental: Period B
Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
Drug: 14C-PF-06651600 IV
IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
Oral solution 200mg
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Male participants who are healthy as determined by medical evaluation including a
detailed medical history, full physical examination, including blood pressure (BP) and
pulse rate (PR) measurement, 12 lead ECG, and clinical laboratory tests.
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
- Known immunodeficiency disorder, including positive serology for human
immunodeficiency virus (HIV) at screening, or a first degree relative with a
- Infection with hepatitis B or hepatitis C viruses.
- Participants with selected acute or chronic infections or infection history.
- Participants have a known present or a history of malignancy other than a successfully
treated or excised non metastatic basal cell or squamous cell cancer of the skin.
- History of alcohol abuse or binge drinking and/or any other illicit drug use or
dependence within 6 months of Screening.
- Use of tobacco/nicotine containing products within 3 months prior to dosing or
positive urine cotinine test.
PRA Health Sciences
PRA Health Sciences Utrecht
Study Director: Pfizer CT.gov Call Center Pfizer